Open this publication in new window or tab >>Show others...
2025 (English)In: BMC Women's Health, E-ISSN 1472-6874, Vol. 25, no 1, article id 0Article in journal (Refereed) Published
Abstract [en]
Background: Cervical cancer is the most prevalent cancer in Mozambique, with endocervical adenocarcinoma accounting for approximately 5.5% of cases. Knowledge regarding the most prevalent HPV genotypes in endocervical adenocarcinoma is limited, within this setting. This study aimed to investigate human papillomavirus (HPV) prevalence and genotypes within a cohort of endocervical adenocarcinoma patients in the context of Mozambique's recently introduced vaccination programme, considering the country's HIV-endemic setting.
Methods: Forty consecutive cases of endocervical adenocarcinoma diagnosed at Maputo Central Hospital between 2017 and 2018, with limited clinical data available, were included. Human immunodeficiency virus (HIV) status was determined through serological data or in situ hybridisation on histopathological slides. HPV detection was performed using a multi-methodological approach, including Anyplex II, in-house polymerase chain reaction (PCR), and chromogenic and fluorescent in situ hybridisation techniques.
Results: All 40 cases exhibited HPV-dependent morphology. Fourteen of the 40 patients were HIV-positive. No significant differences were observed between the two groups regarding age, stage, or histopathological type. hrHPV16, 18, or 45 were detected in all cases. Notably, multiple hrHPV infections were identified exclusively in HIV-negative cases (10/26, p = 0.0075), with hrHPV18/45 co-infection being the most common (n = 8).
Conclusions: These findings suggest that the newly implemented quadrivalent vaccination programme has the potential to prevent morbidity and mortality from endocervical adenocarcinoma, irrespective of HIV infection status, in Mozambique's HIV-endemic environment.
Place, publisher, year, edition, pages
BioMed Central (BMC), 2025
Keywords
Endocervical adenocarcinomas, HIV, HPV, HPV vaccine, In situ hybridisation
National Category
Obstetrics, Gynecology and Reproductive Medicine
Identifiers
urn:nbn:se:oru:diva-118570 (URN)10.1186/s12905-025-03555-z (DOI)001396662000003 ()39815240 (PubMedID)
Note
This research was funded by the Swedish International Development Cooperation Agency (SIDA) to the Universidade Eduardo Mondlane (UEM) for the research training partnership programme UEM_SIDA 2017–2022 as a research programme supporting component. Support from SIDA is part of the European & Developing Countries Clinical Trials Partnership (EDCTP) programme supported by the European Union.
2025-01-162025-01-162025-01-21Bibliographically approved